Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease
Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease
复制标题
DOI：
10.1002/pbc.25905
复制
发表时间：
2016-05-01
影响因子：
3.2
通讯作者：
Liem, Robert I.
中科院分区：
文献类型：
--
作者：
Badawy, Sherif M.;Thompson, Alexis A.;Liem, Robert I.
羟基脲是美国食品和药物管理局（fda）批准的唯一一种治疗镰状细胞病（SCD）的药物，对发病率和死亡率都有短期和长期的益处。然而，羟基脲的利用不足和依从性仍然是SCD患者面临的挑战。本研究的目的是确定患有SCD的青少年和年轻人（AYA）获得技术的途径，并确定他们首选的基于技术的策略来改善药物依从性。从2014年10月到2015年5月，在综合镰状细胞计划中，对患有SCD（所有基因型）的AYA（12-22岁）的各种临床环境进行了横断面调查。结果107名符合条件的参与者中有80人完成了调查，回复率为75%。参与者（51%为女性，94%为黑人）的平均年龄为15.3 - 2.8岁。大多数参与者（75%）每天服用药物，其中约一半服用羟基脲。健忘（67%）是最常见的药物依从性障碍。大多数参与者（85%）拥有智能手机，拥有或可以使用平板电脑（83%）、笔记本电脑（72%）或台式电脑（70%）。在建议的智能手机应用程序功能中，每日药物提醒排在第一位，其次是关于SCD的教育、依从性文本提示、关于SCD药物的教育和用药日志。结论：我们大多数患有SCD的AYA拥有智能手机，并且可以访问其他电子设备。我们的调查结果为开发基于技术的干预措施（如多组件应用程序）的首选应用程序功能和最佳策略提供了有价值的见解，以增加AYA合并SCD或其他慢性病的药物依从性。
BackgroundHydroxyurea is the only Food and Drug Administration approved medication for sickle cell disease (SCD) with short- and long-term benefits for both morbidity and mortality. However, hydroxyurea underutilization and adherence remain challenges for patients with SCD. The objectives of this study were to determine access to technology among adolescents and young adults (AYA) with SCD and to identify their preferred technology-based strategies for improving medication adherence.ProcedureA cross-sectional survey was administered in a variety of clinical settings from October 2014 through May 2015 to AYA (12-22 years) with SCD (all genotypes) followed in a Comprehensive Sickle Cell Program.ResultsEighty of 107 eligible participants completed the survey for a 75% response rate. Participants (51% female, 94% Black) had a mean age of 15.3 2.8 years. Most participants (75%) were on a daily medication with about half on hydroxyurea. Forgetfulness (67%) was the most common barrier to medication adherence. The majority of participants (85%) owned smartphones and either owned or had access to electronic tablets (83%), laptops (72%), or desktops (70%). Of the proposed smartphone app features, daily medication reminders were ranked first most frequently, followed by education about SCD, adherence text prompts, education about SCD medications, and medication log.ConclusionsThe majority of our AYA with SCD owned smartphones and had access to other electronic devices. Our survey results provided valuable insight into the preferred app features and optimal strategies for developing technology-based interventions, such as a multicomponent app, to increase medication adherence for AYA with SCD or other chronic conditions.